alexa Noscapinoids: New Generation Natural α-noscapine Analogues As Potent Tubulin Binding Anticancer Agents
ISSN: 2167-0501

Biochemistry & Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

International Conference on Pharmacognosy, Phytochemistry & Natural Products
October 21-23, 2013 Radisson Blu Plaza Hotel, Hyderabad, India

Srinivas Kantevari
Accepted Abstracts: Biochem & Pharmacol
DOI: 10.4172/2167-0501.S1.004
Abstract
Noscapine (a phthalide-isoquinoline), is an opium alkaloid, widely used as an antitussive agent with little evidence of toxicity. It was discovered as a structural variant of colchicine like molecule that binds to tubulin with a stoichiometry of one noscapine molecule per tubulin dimmer. However, unlike other tubulin binding chemotherapeutic agents that either depolymerise (nocodazole, colchicines, and vinca alkaloids) or over polymerize tubulin (paclitaxel), it just alters tubulin conformation upon binding yet allows its polymerization into microtubules (MTs) but merely suppresses the dynamic instability of microtubules. From a pharmacological perspective, noscapine has many advantages as microtubule binding drugs: it is effective against multidrug- resistant cancer cell line, affects cancer cells differently from the normal diving cells, and has better pharmacokinetics profile with no significant side effects. Although noscapine is cytotoxic in a variety of different cancer cell lines in the public library of the National Cancer Institute, USA (NCI 60-cell screen), and the IC50 values remain in the high micromolar ranges (~21.1 to 100 μM). Thus opportunities must now be explored to acquire better and more effective derivatives, noscapinoids. Indeed, our efforts have been quite encouraging, in that we have some more effective derivative of the lead compound, noscapine. Here, we discuss our results on design, synthesis and evaluation new noscapinoids as potent tubulin binding anticancer agents.
Biography
Srinivas Kantevari obtained his Ph.D. (1996) from Department of Chemistry, Indian Institute of Technology (IIT), New Delhi. He was research associate (1996-97) at National Institute of Immunology (NII) New Delhi. Later, he was a post-doctoral fellow (2001-2003) and research associate (2006-2008) with Prof. Graham Ellis-Davies, Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, USA. He has been associated with Indian Institute of Chemical Technology (IICT) since 1997. Presently, he is sr. scientist at Indian Institute of Chemical Technology (IICT), Hyderabad. His research interests are broad based which include development of new photolabile compounds to control cellular chemistry, development new drug candidates and imaging agents for probing Alzheimer?s disease (AD), receptor targeted approaches for the development of new chemical entities, fragment based approaches for drug design and discovery. He has been able to successfully carry out extensive basic and applied research investigations in the chemistry of new molecules derived from natural products of biological relevance. Presently, 7 students are working for Ph.D. and 4 students for master?s dissertation work. He has 62 publications and 5 patents for his credit. He is an editorial board member for Open Journal of Catalysis, member, and editorial board of reviewers for ARKIVOC, and expert reviewer for various journals of international reputation. He also developed several processes for APIs and drug molecules of interest and involved in transferring the technologies.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords